Relief Therapeutics Holding AG
SIX:RLF.SW
5.2 (CHF) • At close October 17, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) CHF.
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue
| 6.033 | 6.081 | 3.321 | 0 | 0 | 0.567 | 0 | 0.015 | 0.256 | 19.49 | 20.714 | 0 | 0 | 0.386 | 13.74 | 14.545 | 14.827 |
Cost of Revenue
| 16.892 | 18.108 | 11.907 | 0 | 0.001 | 0.055 | 0.003 | 0.211 | 2.082 | 12.683 | 13.395 | 1.904 | 0 | 0 | 0 | 0 | 0 |
Gross Profit
| -10.859 | -12.027 | -8.586 | 0 | -0.001 | 0.512 | -0.003 | -0.196 | -1.826 | 6.807 | 7.32 | -1.904 | 0 | 0.386 | 13.74 | 14.545 | 14.827 |
Gross Profit Ratio
| -1.8 | -1.978 | -2.585 | 0 | 0 | 0.903 | 0 | -13.067 | -7.131 | 0.349 | 0.353 | 0 | 0 | 1 | 1 | 1 | 1 |
Reseach & Development Expenses
| 1.328 | 12.393 | 19.024 | 13.645 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.904 | 54.7 | 14.548 | 20.146 | 20.173 | 11.291 |
General & Administrative Expenses
| 17.229 | 7.747 | 5.65 | 2.838 | 0.566 | 0.643 | 0.704 | 0.905 | 0.028 | 2.192 | 0.513 | 3.72 | 2.672 | 1.683 | 2.071 | 1.191 | 1.509 |
Selling & Marketing Expenses
| 2.2 | 3.307 | 0.365 | 2.654 | 0.349 | 0.346 | 0.989 | 0.04 | 0 | 0.03 | 0.066 | 0.556 | 1.796 | 3.403 | 3.632 | 2.351 | 3.762 |
SG&A
| 7.533 | 10.819 | 6.935 | 5.492 | 0.915 | 0.989 | 1.242 | 0.945 | 0.028 | 2.222 | 0.58 | 4.276 | 4.467 | 5.087 | 5.703 | 3.541 | 5.27 |
Other Expenses
| -0.184 | -1.308 | -0.665 | -0.161 | -0.031 | -0.006 | 0 | 0.792 | 1.965 | 1.312 | 18.213 | -1.686 | 0 | 0 | 0 | 0 | 0 |
Operating Expenses
| 9.045 | 24.52 | 26.624 | 19.298 | 0.946 | 0.788 | 1.242 | 1.737 | 1.993 | 20.477 | 18.793 | 4.494 | 59.167 | 19.634 | 25.848 | 23.714 | 16.562 |
Operating Income
| -19.904 | -36.547 | -35.21 | -19.298 | -0.947 | -0.5 | -1.245 | -16.489 | -3.819 | -12.104 | -11.473 | -6.18 | -59.167 | -19.248 | -12.108 | -9.169 | -1.734 |
Operating Income Ratio
| -3.299 | -6.01 | -10.602 | 0 | 0 | -0.882 | 0 | -1,099.267 | -14.911 | -0.621 | -0.554 | 0 | 0 | -49.816 | -0.881 | -0.63 | -0.117 |
Total Other Income Expenses Net
| -91.78 | -17.769 | -0.315 | 13.037 | -11.215 | 0.084 | -0.656 | -0.325 | -0.548 | 1.217 | -0.963 | -0.305 | 0.001 | -0.149 | -0.114 | -0.232 | -0.654 |
Income Before Tax
| -111.684 | -54.316 | -35.525 | -6.261 | -12.162 | -0.416 | -1.901 | -16.814 | -4.367 | -12.454 | -12.436 | -6.485 | -59.166 | -19.397 | -12.222 | -9.401 | -1.765 |
Income Before Tax Ratio
| -18.512 | -8.932 | -10.697 | 0 | 0 | -0.734 | 0 | -1,120.933 | -17.051 | -0.639 | -0.6 | 0 | 0 | -50.202 | -0.889 | -0.646 | -0.119 |
Income Tax Expense
| -13.503 | -3.526 | -0.82 | 1.567 | -4.702 | 0.02 | 0.986 | 0.02 | -0.088 | -0.171 | -0.217 | -0.318 | -0.001 | 0.149 | -0.008 | 0.232 | 0.235 |
Net Income
| -98.181 | -50.79 | -34.705 | -7.828 | -7.46 | -0.436 | -2.887 | -16.834 | -9.154 | -12.28 | -12.171 | -6.485 | -59.166 | -19.397 | -12.214 | -9.401 | -2 |
Net Income Ratio
| -16.274 | -8.352 | -10.45 | 0 | 0 | -0.769 | 0 | -1,122.267 | -35.743 | -0.63 | -0.588 | 0 | 0 | -50.202 | -0.889 | -0.646 | -0.135 |
EPS
| -8.35 | -4.8 | -3.86 | -1.3 | -1.42 | -0.085 | -0.58 | -5.32 | -6.24 | -10.34 | -28.41 | -37.2 | -343.4 | -116.67 | -9.02 | -7.21 | -7.67 |
EPS Diluted
| -8.35 | -4.8 | -3.86 | -1.3 | -1.42 | -0.085 | -0.58 | -5.32 | -6.24 | -10.34 | -28.41 | -37.2 | -343.4 | -116.67 | -9.02 | -7.21 | -7.67 |
EBITDA
| -16.586 | -32.687 | -33.174 | -19.298 | -0.946 | -0.483 | -1.242 | -2.245 | -2.135 | -6.022 | -9.917 | -6.407 | -56.88 | -15.381 | -8.189 | -4.977 | 2.27 |
EBITDA Ratio
| -2.749 | -5.375 | -9.989 | 0 | 0 | -0.852 | 0 | -149.667 | -8.338 | -0.309 | -0.479 | 0 | 0 | -39.808 | -0.596 | -0.342 | 0.153 |